ESKAPE

ESKAPE is an acronym standing for bacterial pathogens commonly associated with antimicrobial resistance. ESKAPE is group of pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species).

ESKAPE pathogens are considered the leading cause of nosocomial (hospitalborn) and hospital acquired infections throughout the world. Two, an Indian company, Bangalore-based Bugworks Research, has received an Initial fund of $ 2.6 million for its work on a new class of antibiotics to fight what is known as the ―ESKAPE.